Encouraging better use of tests

  1. Sturgeon C. Tumour Markers. Chapter 42 in Clinical Chemistry (3rd ed), eds WJ Marshall, M Lapsley, A Day and R Ayling. 2013: Churchill Livingstone.
  2. Hanon EA, Sturgeon C, Lamb EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Clin Lab Med 2013; 51: 1925-41
  3. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers (EGTM) 2013 guidelines update. Int J Cancer 2014; 134: 2513-22
  4. Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem 2011; 48: 418-32
  5. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem 2011; 48: 295-9
  6. Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128: 3-11
  7. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010: 56: e1-48
  8. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010; 21: 441-7
  9. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009 Sept 22; 339:b3527
  10. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem 2008; 54: e11-79
  11. Sturgeon CM, Hoffman BR, Chan DW, Ch’ng SL, Hammond E, Hayes DF, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality requirements. Clin Chem 2008; 54: e1-10


  1. Berger P, Sturgeon C. Pregnancy testing with hCG – future prospects. Trends Endocrinol Metab 2014 25: 637-648
  2. Sturgeon CM. Common decision limits – The need for harmonised immunoassays. Clin Chim Acta 2014 432: 122-6
  3. Wieringa GE, Sturgeon CM, Trainer PJ. The harmonisation of growth hormone measurements: Taking the next steps. Clin Chim Acta 2014 432: 68-71
  4. Berger P, Paus E, Hemken PM, Sturgeon C, Stewart WW, Skinner JP et al. Candidate epitopes for measurement of hCG and related molecules: the second ISOBM TD-7 workshop. Tumour Biol 2013; 34: 4033-57
  5. Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, et al. Design of tumor biomarker-monitoring trials: a proposal by the European group on tumor markers. Clin Chem 2013 59: 52-9.
  6. Boulo S, Hanisch K, Bidlingmaier M, Arsène C-G, Panteghini M, Auclair G, Sturgeon C, et al. Gaps in the traceability chain of human growth hormone measurements. Clin Chem 2013 59: 1074-82
  7. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results – a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011; 26: 3440-5.
  8. Miller WG, Myers Gl, Gantzer ML, Kahn SE, Schonbrunner ER, Thienpont LM, et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2011; 57: 1108-17.
  9. Sturgeon CM, Berger P, Bidart JM, Birken S, Burns C, Norman RJ, Stenman UH. IFCC Working Group on hCG. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem 2009; 55:1484-91.
  10. Berger P and Sturgeon CM. Human chorionic gonadotropin (hCG) isoforms and their epitopes: diagnostic utility in pregnancy and cancer. Expert Opinion Med Diag. 2008; 2: 1347-64.

EQA of new and established biomarkers

  1. Sturgeon CM. External quality assessment of hormone determinations. Best Practice & Research Clinical Endocrinology & Metabolism 2013; 27: 803-22
  2. Sturgeon C. External quality assessment schemes for immunoassays. Methods Mol Biol. 2013;1065: 291-305
  3. Sturgeon C. Quality Assurance. Chapter 6.2 in The Immunoassay Handbook (4th ed), ed D Wild, 2013: Elsevier.
  4. Kift RL, Messenger MP, Wind TC, Hepburn S, Wilson M, Thompson D, et al. A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine. Ann Clin Biochem 2013; 50: 236-44
  5. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use – A perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010; 4: 892-903.
  6. Sturgeon C, Selby P. Development and validation of new biomarkers: major opportunities for healthcare scientists. Ann Clin Biochem. 2010; 47: 499-502.
  7. Sturgeon C. Perspectives in Clinical Proteomics Conference: translating clinical proteomics into clinical practice. [Meeting report] Expert Rev Proteomics 2010; 7: 469-71.